Mismatch repair deficiency in bilateral breast cancer

Mismatch repair deficiency in bilateral breast cancer

Abstract Background Since the FDA approved immune-enhancing therapies for patients with high microsatellite instability (MSI-H) and/or mismatch repair deficiency (dMMR), recognizing these biomarkers in solid tumors has gained clinical importance. Although MSI-H and dMMR are considered uncommon in br...

Full description

Bibliographic Details
Main Authors: Milena Massumi Kozonoe, Jacqueline Justino Nabhen, Bruno Ribeiro Batista, Lucas Novello, Edenir Inêz Palmero, Sérgio Ossamu Ioshii, Júlia Costa Linhares
Format: Article
Language:English
Published: BMC 2024-08-01
Series:Surgical and Experimental Pathology
Subjects:
Breast cancer
Bilateral breast cancer
Microsatellite instability
Mismatch repair deficiency
Mutational load
Immunotherapy
Online Access:https://doi.org/10.1186/s42047-024-00156-2

Internet

https://doi.org/10.1186/s42047-024-00156-2

Similar Items